恩威医药 (301331)

Enwei Pharmaceutical Co., Ltd.

ASZ

Tags

Special Purpose LoansMicro Cap StocksHigh Pledged StocksShenzhen Recently Listed StocksChinese Med. IISZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexChiNext Composite IndexCSI All-share Pharmaceutical Sector IndexShareholding Increase CommitmentTibet ConceptPrivate Enterprise Development Index

K-Line Chart

No K-line data available

Company NameEnwei Pharmaceutical Co., Ltd.
Listing Date2022-09-21
Issue Price29.8RMB
Registered Capital10289.188710k RMB
Legal RepresentativeXue Yongjiang
Registered AddressEnwei Building, Chuangye Avenue, A Dam Area, Economic Development Zone, Changdu City, Tibet Autonomous Region
IndustryTraditional Chinese Medicine II
Main BusinessResearch, development, production, and sales of Chinese patent medicines and chemical drugs
Company ProfileEnwei Pharmaceutical Co., Ltd. is primarily engaged in the research, development, production, and sales of Chinese patent medicines and chemical drugs, focusing on gynecological products, pediatric medications, and respiratory system drugs. The company has established a production system in compliance with GMP requirements and adopts a sales model primarily based on distribution, supplemented by direct sales and e-commerce. The company has been deeply involved in the gynecological product field for many years. According to data from Menet, from 2015 to 2020, its core product "Jie'eryin Lotion" ranked first in market share in the Chinese patent medicine segment for gynecological inflammation in China's urban retail pharmacies for six consecutive years. The company's main products are OTC drugs. Since its establishment, the company has continuously improved its coverage of terminal retail pharmacies. The total number of retail pharmacies in China exceeded 550,000 in 2020 (data source: "2021 China Pharmaceutical Market Development Blue Book"), and the number of pharmacies maintained by the company's own team has reached approximately 60,000.

Stock Details

1. Key Indicators

  • Total Shares(W): 10289.19
  • Circulating A-Shares(W): 10269.58
  • Earnings Per Share(RMB): 0.3668
  • Net Assets Per Share(RMB): 10.5319
  • Operating Revenue(W RMB): 63685.36
  • Total Profit(W RMB): 4318.76
  • Net Profit Attributable to Parent(W RMB): 3658.47
  • Net Profit Growth Rate(%): 66.13
  • Weighted Return on Equity(%): 3.4200
  • Operating Cash Flow Per Share(RMB): 0.7410
  • Undistributed Profit Per Share(RMB): 3.4670
  • Capital Reserve Per Share(RMB): 6.2813

2. Main Business

The main business covers:

  • Research, production, and sales of Chinese patent medicines
  • Research, production, and sales of chemical drugs
  • Research, production, and sales of health and personal care products

3. Company Basic Information

  • Company Name: Enwei Pharmaceutical Co., Ltd.
  • Listing Date: 2022-09-21
  • Industry: Pharmaceutical Manufacturing
  • Address: Enwei Building, Chuangye Avenue, A Dam Area, Economic Development Zone, Changdu City, Tibet Autonomous Region
  • Website: www.enwei.com.cn
  • Company Profile: On January 12, 2018, the shareholders' meeting of the limited company passed a resolution to establish a joint-stock company with 11 shareholders including Enwei Group, Chengdu Jiewei, Chengdu Ruijinheng, Chengdu Zehong, Changdu Jieweite, Changdu Jiwei, Changdu Xiangwei, Changdu Changwei, Changdu Longwei, Changdu Huiwei, and Changdu Shengwei as the promoters. Based on the audited net asset value of RMB 251,607,195 as of September 30, 2017, the net assets were converted into 51,020,408 shares of the joint-stock company at a ratio of 4.9315:1, with a par value of RMB 1 per share. The excess of net assets over share capital was recorded as capital reserve of the joint-stock company. On January 12, 2018, the 11 shareholders of Enwei Limited signed the promoter agreement, stipulating that all shareholders of Enwei Limited would act as promoters to change the company's organizational form from a limited liability company to a joint-stock company. On January 29, 2018, Enwei Pharmaceutical held its inaugural meeting and first shareholders' meeting. On January 13, 2018, ShineWing issued the capital verification report XYZH/2018CDA30028, confirming that as of January 13, 2018, the company had received the audited net assets converted into registered capital of RMB 51,020,408. On February 2, 2018, Enwei Pharmaceutical obtained the business license with Unified Social Credit Code 91540300741923208K issued by the Changdu City Administration for Industry and Commerce, Tibet Autonomous Region.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chengdu Enwei Investment (Group) Co., Ltd. General Legal Person 2973.32 28.95
2 Chengdu Jiewei Enterprise Management Co., Ltd. General Legal Person 1410.30 13.73
3 Chengdu Ruijinheng Enterprise Management Co., Ltd. General Legal Person 1288.41 12.55
4 Chengdu Zehong Enterprise Management Co., Ltd. General Legal Person 1288.41 12.55
5 Changdu Jieweite Enterprise Management Co., Ltd. General Legal Person 149.67 1.46
6 Changdu Longwei Enterprise Management Partnership (Limited Partnership) General Legal Person 51.59 0.50
7 China Merchants Securities Asset Management Zhida Quantitative Stock Selection Hybrid Initiated Securities Investment Fund Class A Fund 0.79 0.01

5. Concept Sectors

  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Micro-cap Stocks
  • High Pledge Ratio Stocks
  • Special Loans

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information